Arena Defends Obesity Drug After Phase III BLOOM Wilts
This article was originally published in The Pink Sheet Daily
Executive Summary
Like Orexigen’s Contrave, Arena’s lorcaserin meets one of two FDA efficacy standards – enough for approval, but not a roaring success.